RenovoRx, Inc.

RNXT Nasdaq CIK: 0001574094

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040
Mailing Address 2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW, CA, 94040
Phone 408-800-2649
Fiscal Year End 1231
EIN 271448452

Financial Overview

FY2025 FY

$1.12M
Revenue
$5.42M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
S-3 Shelf registration for future offerings April 16, 2026 View on SEC
4 Insider stock transaction report April 7, 2026 View on SEC
4 Insider stock transaction report April 7, 2026 View on SEC
4 Insider stock transaction report April 7, 2026 View on SEC
4 Insider stock transaction report April 7, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
10-K Annual financial report March 30, 2026 View on SEC
8-K Current report of material events March 27, 2026 View on SEC
4 Insider stock transaction report March 27, 2026 View on SEC
3 Initial insider ownership report March 24, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • Transitioned from research to commercial operations with $1.1 million in 2025 revenue.
  • Pipeline tripled to 33 U.S. cancer centers, with 12 active and 21 in evaluation.
View Analysis

Material Events

8-K Financial Distress January 2, 2026
High Impact
  • RenovoRx, Inc. received a formal warning from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share.
  • The company's common stock traded below $1.00 for 32 consecutive business days, putting its Nasdaq listing at risk.

Insider Trading

BUY 4 insiders 6 recent transactions
View Insider Trading Dashboard

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.